Eagle Veterinary Technology Co.Ltd (044960) - Net Assets
Based on the latest financial reports, Eagle Veterinary Technology Co.Ltd (044960) has net assets worth ₩50.42 Billion KRW (≈ $34.17 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩60.77 Billion ≈ $41.18 Million USD) and total liabilities (₩10.35 Billion ≈ $7.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Eagle Veterinary Technology Co.Ltd (044960) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩50.42 Billion |
| % of Total Assets | 82.97% |
| Annual Growth Rate | 5.26% |
| 5-Year Change | 28.76% |
| 10-Year Change | 57.1% |
| Growth Volatility | 2.39 |
Eagle Veterinary Technology Co.Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Eagle Veterinary Technology Co.Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Eagle Veterinary Technology Co.Ltd for the complete picture of this company's asset base.
Annual Net Assets for Eagle Veterinary Technology Co.Ltd (2014–2024)
The table below shows the annual net assets of Eagle Veterinary Technology Co.Ltd from 2014 to 2024. For live valuation and market cap data, see Eagle Veterinary Technology Co.Ltd (044960) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩48.59 Billion ≈ $32.93 Million |
+7.16% |
| 2023-12-31 | ₩45.34 Billion ≈ $30.73 Million |
+5.56% |
| 2022-12-31 | ₩42.95 Billion ≈ $29.11 Million |
+5.20% |
| 2021-12-31 | ₩40.83 Billion ≈ $27.67 Million |
+8.20% |
| 2020-12-31 | ₩37.74 Billion ≈ $25.57 Million |
+6.20% |
| 2019-12-31 | ₩35.53 Billion ≈ $24.08 Million |
+2.86% |
| 2018-12-31 | ₩34.55 Billion ≈ $23.41 Million |
+8.25% |
| 2017-12-31 | ₩31.91 Billion ≈ $21.63 Million |
+0.81% |
| 2016-12-31 | ₩31.66 Billion ≈ $21.45 Million |
+2.35% |
| 2015-12-31 | ₩30.93 Billion ≈ $20.96 Million |
+6.24% |
| 2014-12-31 | ₩29.11 Billion ≈ $19.73 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Eagle Veterinary Technology Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 220.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩25.37 Billion | 52.22% |
| Common Stock | ₩6.32 Billion | 13.01% |
| Other Components | ₩16.90 Billion | 34.78% |
| Total Equity | ₩48.59 Billion | 100.00% |
Eagle Veterinary Technology Co.Ltd Competitors by Market Cap
The table below lists competitors of Eagle Veterinary Technology Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Risma Systems AS
CO:RISMA
|
$33.94 Million |
|
TPC CONSOLIDATED LTD.
F:T7P
|
$33.95 Million |
|
Samil Enterprise Co. Ltd
KQ:002290
|
$33.95 Million |
|
Dr Peng Telecom and Media Group Co Ltd
SHG:600804
|
$33.96 Million |
|
ENERGIA IN.Y DES. EO 025
F:F63
|
$33.92 Million |
|
Softcat plc
LSE:SCT
|
$33.91 Million |
|
Mendus AB (publ)
ST:IMMU
|
$33.90 Million |
|
Neuroone Medical Technologies Corp
NASDAQ:NMTC
|
$33.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eagle Veterinary Technology Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 45,343,016,340 to 48,589,838,960, a change of 3,246,822,620 (7.2%).
- Net income of 3,705,275,820 contributed positively to equity growth.
- Dividend payments of 490,995,880 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.71 Billion | +7.63% |
| Dividends Paid | ₩491.00 Million | -1.01% |
| Other Changes | ₩32.54 Million | +0.07% |
| Total Change | ₩- | 7.16% |
Book Value vs Market Value Analysis
This analysis compares Eagle Veterinary Technology Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.44x to 1.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2751.02 | ₩3960.00 | x |
| 2017-12-31 | ₩2823.79 | ₩3960.00 | x |
| 2018-12-31 | ₩2814.38 | ₩3960.00 | x |
| 2019-12-31 | ₩2894.77 | ₩3960.00 | x |
| 2020-12-31 | ₩3074.19 | ₩3960.00 | x |
| 2021-12-31 | ₩3326.27 | ₩3960.00 | x |
| 2022-12-31 | ₩3499.36 | ₩3960.00 | x |
| 2023-12-31 | ₩3693.96 | ₩3960.00 | x |
| 2024-12-31 | ₩3958.47 | ₩3960.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eagle Veterinary Technology Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.63%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.88%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.26x
- Recent ROE (7.63%) is above the historical average (5.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 3.53% | 5.08% | 0.49x | 1.43x | ₩-1.88 Billion |
| 2015 | 3.34% | 4.12% | 0.57x | 1.42x | ₩-2.06 Billion |
| 2016 | 7.06% | 7.75% | 0.62x | 1.46x | ₩-931.53 Million |
| 2017 | 4.87% | 4.55% | 0.69x | 1.56x | ₩-1.64 Billion |
| 2018 | 3.02% | 3.44% | 0.66x | 1.33x | ₩-2.41 Billion |
| 2019 | 3.47% | 3.58% | 0.75x | 1.29x | ₩-2.32 Billion |
| 2020 | 6.52% | 6.09% | 0.83x | 1.28x | ₩-1.31 Billion |
| 2021 | 8.91% | 9.00% | 0.77x | 1.29x | ₩-445.12 Million |
| 2022 | 6.15% | 6.07% | 0.79x | 1.28x | ₩-1.65 Billion |
| 2023 | 6.56% | 6.95% | 0.73x | 1.29x | ₩-1.56 Billion |
| 2024 | 7.63% | 8.88% | 0.68x | 1.26x | ₩-1.15 Billion |
Industry Comparison
This section compares Eagle Veterinary Technology Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $93,514,224,134
- Average return on equity (ROE) among peers: 3.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eagle Veterinary Technology Co.Ltd (044960) | ₩50.42 Billion | 3.53% | 0.21x | $33.93 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $148.52 Billion | 5.89% | 0.76x | $5.86 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $72.10 Billion | 6.34% | 0.45x | $32.48 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $685.93 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $66.92 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $88.30 Million |
| WooGene B&G Co. Ltd (018620) | $21.90 Billion | 1.61% | 0.93x | $13.13 Million |
| Oscotec Inc (039200) | $46.29 Billion | 7.50% | 0.52x | $971.25 Million |
| EstechPharma Co. Ltd (041910) | $67.96 Billion | 5.45% | 0.54x | $60.00 Million |
| Komipharm International Co. Ltd (041960) | $44.72 Billion | 0.00% | 1.43x | $366.32 Million |
About Eagle Veterinary Technology Co.Ltd
Eagle Veterinary Technology Co.,Ltd manufactures and sells animal health care products in South Korea. The company offers antibiotics, antibacterials, anthelmintics, antihistamins, and in the form of injectable, feed additives, oral liquids, and soluble powders for swine, poultry, and bovine. Eagle Veterinary Technology Co.,Ltd also exports its products to New Zealand, Australia, Vietnam, Kenya, … Read more